PSUSA/00002904/202509
Submitted by Anonymous (not verified) on 11 May 2026 - 15:15
PSUSA/00002904/202509
PSUSA/00010582/202509
Submitted by Anonymous (not verified) on 11 May 2026 - 15:10
PSUSA/00010582/202509
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 15:03
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Exdensur, depemokimab, Date of authorisation: 12/02/2026, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 15:00
Human medicines European public assessment report (EPAR): Exdensur, depemokimab, Date of authorisation: 12/02/2026, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Qalsody, tofersen, Date of authorisation: 29/05/2024, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 14:55
Human medicines European public assessment report (EPAR): Qalsody, tofersen, Date of authorisation: 29/05/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 14:50
Human medicines European public assessment report (EPAR): Amglidia, glibenclamide, Date of authorisation: 24/05/2018, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Giotrif, afatinib, Date of authorisation: 25/09/2013, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 14:37
Human medicines European public assessment report (EPAR): Giotrif, afatinib, Date of authorisation: 25/09/2013, Revision: 18, Status: Authorised
Learning Objectives: Focus on Practical Aspects of Hereditary Angioedema
Submitted by Catalina on 11 May 2026 - 14:13
The EFIM Rare Diseases Working Group is pleased to invite you to our upcoming webinar, “Learning Objectives: Focus on Practical Aspects of Hereditary Angioedema,” taking place on, 10 June 2026, from 17:00 to 18:00 CET. This session will address key aspects of Hereditary Angioedema such as when to suspect, management, and future therapies of HAE, featuring guest speaker: Prof. Markus Magerl. Join us for this insightful session and engage with experts.
Human medicines European public assessment report (EPAR): Orencia, abatacept, Date of authorisation: 21/05/2007, Revision: 43, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 14:05
Human medicines European public assessment report (EPAR): Orencia, abatacept, Date of authorisation: 21/05/2007, Revision: 43, Status: Authorised
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 11 May 2026 - 14:00
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised